{"slideshow_credits": null, "snippet": "While the company gave no reason in a statement announcing the revised forecast, it has been dealing with controversies over its pricing and distribution.", "abstract": "Valeant Pharmaceuticals says it expects 2015 revenue of $10.4 billion to $10.5 billion, down from earlier forecast of $11 billion to $11.2 billion; earnings per share are forecast at $10.23 to $10.33.", "section_name": "Business Day", "print_page": "3", "document_type": "article", "byline": {"person": [{"firstname": "Andrew", "role": "reported", "lastname": "POLLACK", "rank": 1, "organization": ""}], "original": "By ANDREW POLLACK"}, "web_url": "http://www.nytimes.com/2015/12/17/business/valeant-lowers-guidance-investors-meeting.html", "lead_paragraph": "While the company gave no reason in a statement announcing the revised forecast, it has been dealing with controversies over its pricing and distribution.", "headline": {"main": "Valeant Pharmaceuticals Cuts Earnings and Sales Forecasts", "print_headline": "Valeant Cuts Its Forecast for Earnings and Sales"}, "_id": "56716a4938f0d803bb110e81", "word_count": "879", "multimedia": [{"height": 126, "url": "images/2015/12/17/business/17valeant-web1/17valeant-web1-thumbWide.jpg", "legacy": {"wideheight": "126", "wide": "images/2015/12/17/business/17valeant-web1/17valeant-web1-thumbWide.jpg", "widewidth": "190"}, "subtype": "wide", "width": 190, "type": "image"}, {"height": 397, "url": "images/2015/12/17/business/17valeant-web1/17valeant-web1-articleLarge.jpg", "legacy": {"xlarge": "images/2015/12/17/business/17valeant-web1/17valeant-web1-articleLarge.jpg", "xlargewidth": "600", "xlargeheight": "397"}, "subtype": "xlarge", "width": 600, "type": "image"}, {"height": 75, "url": "images/2015/12/17/business/17valeant-web1/17valeant-web1-thumbStandard.jpg", "legacy": {"thumbnail": "images/2015/12/17/business/17valeant-web1/17valeant-web1-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "subtype": "thumbnail", "width": 75, "type": "image"}], "pub_date": "2015-12-17T00:00:00Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"name": "organizations", "value": "Valeant Pharmaceuticals International Inc", "is_major": "Y", "rank": "1"}, {"name": "subject", "value": "Company Reports", "is_major": "N", "rank": "2"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "is_major": "N", "rank": "3"}], "blog": [], "subsection_name": null, "type_of_material": "News"}